

SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Authors: Constantine S. Tam,¹ Paolo Ghia,^{2,3} Mazyar Shadman,^{4,5} Talha Munir,⁶ Stephen S. Opat,⁷ Patricia A. Walker,⁸ Masa Lasica,⁹ Ian W. Flinn,¹⁰ Tian Tian,¹¹ Stephanie Agresti,¹¹ Jamie Hirata,¹¹ Jennifer R. Brown¹²

Affiliations: ¹Alfred Hospital and Monash University, Melbourne, VIC, Australia; ²Università Vita-Salute San Raffaele, Milano, Italy; ³IRCCS Ospedale San Raffaele, Milano, Italy; ⁴Fred Hutchinson Cancer Center, Seattle, WA, USA; ⁵University of Washington, Seattle, WA, USA; ⁶Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁷Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; ⁸Peninsula Health and Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia; ⁹St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; ¹⁰Tennessee Oncology/OneOncology, Nashville, TN, USA; ¹¹BeiGene USA, Inc, San Mateo, CA, USA; ¹²Dana-Farber Cancer Institute, Boston, MA, USA

Background: Zanubrutinib (zanu) is a next-generation Bruton tyrosine kinase inhibitor that is approved for 5 indications, including CLL/SLL. Initial results from the SEQUOIA study (NCT03336333), at a median follow-up of 26.2 mo, demonstrated superior progression-free survival (PFS) by independent review with zanu vs bendamustine + rituximab (arms A and B) in patients (pts) with treatment-naïve (TN) CLL/SLL without del(17p) as well as high overall response rate (ORR) and PFS benefit in pts with del(17p) (arm C). Additionally, the 5-y follow-up in arm A demonstrated durable PFS benefit, with estimated 54- and 60-mo PFS rates of 80% and 76%, respectively. Here we report updated results in SEQUOIA arm C, in pts with del(17p), after approximately 5 y of follow-up (data cutoff: Apr 30, 2024).

Methods: Arm C is a nonrandomized cohort of SEQUOIA pts with del(17p) that received zanu monotherapy. Investigator-assessed PFS, overall survival (OS), ORR, and safety/tolerability were evaluated. Adverse events (AEs) were recorded until disease progression or start of next-line therapy.

Results: Between Feb 2018 and Mar 2019, 111 TN pts with del(17p) were enrolled to receive zanu. The median age was 71 y (range, 42-87 y), 79 (71%) were male, 67 (60%) were IGHV unmutated, and 47 (42%) had both del(17p) and *TP53* mutation. At a median follow-up of 65.8 mo (range, 5-75 mo), median PFS was not reached. The estimated 60-mo PFS rate was 72.2% (62.4%-79.8%), or 73.0% (63.3%-80.6%) when adjusted for COVID-19. Median OS was also not reached. The estimated 60-mo OS rate was 85.1% (76.9%-90.6%), or 87.0% (79.0%-92.1%) when adjusted for COVID-19. The ORR was 97.3%, and the complete response/complete response with incomplete hematologic recovery rate was 18.2%. Zanu treatment was ongoing in 62.2% of pts. The most common causes for treatment discontinuation were AEs and progressive disease (in 17.1% and 15.3%, respectively). Key AEs of interest (AEI) included any-grade infection (82%), bleeding (60%), neutropenia (19%), hypertension (18%), anemia (9%), thrombocytopenia (8%), and atrial fibrillation/flutter (7%). Grade ≥ 3 AEI included infection (33%), neutropenia (16%), hypertension (8%), bleeding (6%), atrial fibrillation/flutter (5%), and thrombocytopenia (2%).

Conclusions: With this 5-y follow-up in SEQUOIA, the efficacy of zanu in TN higher-risk pts with del(17p) was maintained, and pts continue to demonstrate PFS benefits consistent with the randomized cohort of pts without del(17p) (arm A). Additionally, with longer-term follow-up, no

new safety signals were identified. This update, in the largest cohort of uniformly treated pts with del(17p), suggests that zanu remains a valuable frontline treatment option for patients with or without del(17p) CLL/SLL.